1Snijders PJ, Steenbergen RD, Heideman DA, et al. HPV- mediated cervical carcinogenesis: concepts and clinical implications[ J]. J Pathol,2006,208 : 152-164.
2Patricia C, Anne R, Alexia S, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype [J]. Int J Cancer,2009, 124:778-782.
3Schellekens MC, Dijkman A ,Aziz MF, et al. Prevalence of single and multiple HPV types in cervical carcinomas in jakarta,Indonesia[ J]. Gynecol Oncol,2004,93:49.
4Belinson J, Qiao YL, Pretorius R, et al. Prevalence of cervical cancer and feasibility of screening in rural China:a pilot study for the Shanxi province cervical cancer screening study [ J ]. Int J Gynecol Cancer, 1999,9:411-417.
10Song SH, Park HM, Eom DW, et al. The expression of P16INK4a and Ki67 in relation to high risk human papilloma viral load and residual disease after conization with positive margins [ J ]. Int J Gynecol Cancer, 2007,17 : 858-867.
5De Francesco MA, Gargiulo F, Schreiber C, et al. Detection and genotyping of human papillomavirus in cervical sampies from Italian patients [ J ]. J Med Virol, 2005,75 : 588- 592
6Cox JT. Human papillomavirus testing in primary cervical screening and abnormal papanicolaou management [ J ]. Obstet Gynecol Surv,2006,61 :S15-25
7Ordi J, Alonso I, Tome A, et al. Human papillomavirus load in Hybrid Capture Ⅱ assat:does increasing the cutoff improve the test? [ J] Gynecol Oncol,2005 ,99 :313-319
8Wu Y, Chen Y, Li L, et al. Associations of high-risk HPV types and viral load with cervical cancer in China [ J ]. J Clin Virol,2006,35:264-269
9Oddi J, Puig-Tintore LM, Tome A, et al. Contribution of high risk human papillomavirus testing to the management of premalignant and malignant lesions of the uterine cervix [J]. Med J Clin,2003,121:441-445
10Riethmuller D, Gay C, Bertrand X, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture Ⅱ and polymerase chain reaction [ J ]. Di- agn Mol Pathol, 1999 ;8 : 157-164
5Kim Y J, Kim KT, Kim JH, et al. Vaccination with a human papillo- mavirus (HPV) -16/18 AS04 -adjuvanted cervical eancer vaccine in Korean girls aged 10 -14 years[J]. J Korean Med Sci, 2010, 25 (8) : 1197.
6Giorgi RP, Bisanzi S, Paganini I, et al. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study [J] . BMC Infect Dis, 2010, 10:214.
7Dalste i n V,R i ethm ull e t D,Pretet J L,et al.Persistentand load of hi gh risk HPV arepredictors for development of high grade cervical lesions:A long it udinal Freach cohort study[J].Int J Cancer,2003; 106:396-403.
8Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer[J].Clinical Science(London),2006.525-541.
9Guido R,Schiffman M,Solomon D. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesion or human papillomavirus DNA-positive atypical squamous cells of undermined significance:a two year prospective study[J].American Journal of Obstetrics and Gynecology,2003.1401-1405.
10Ungureanu C,Socolov D,Anton G. Immunocytochemical expression of p16INK4a and HPV L1 capsid proteins as predictive markers of the cervical lesions progression risk[J].Romanian Journal of Morphology and Embryology,2010.497-503.
